The Food and Drug Administration approved Orzeyful (oveporexton) tablets on August 5, 2026 for adults with narcolepsy type 1, the first medicine cleared to treat the disease by replacing the brain chemical patients have lost instead of managing symptoms one at a time. It is the first drug approved that works by directly activating the orexin system, and the FDA based the decision on two 12-week trials in 273 adults. Side effects were common, the most frequent being insomnia, increased urinary frequency and urgency, and increased saliva.
Key takeaways
- Orzeyful is the first orexin receptor agonist ever approved, and the first drug aimed at the cause of narcolepsy type 1 rather than its symptoms.
- Insomnia and increased urinary frequency were among the most common side effects in the trials.
- It is not available yet. The Drug Enforcement Administration has not issued its controlled substance scheduling decision, and the drug can be marketed only once that decision comes.
What happened
Narcolepsy type 1 affects an estimated 1 in 2,000 people in the United States, according to the FDA, which Takeda puts at roughly 120,000 Americans. The FDA describes it as a disease “caused by the loss of brain cells that produce orexin, a chemical messenger that regulates wakefulness, sleep, and muscle tone.” Losing that signal causes daytime sleepiness no amount of rest fixes, cataplexy (sudden muscle weakness set off by strong emotion such as laughter), sleep paralysis, hallucinations at the edge of sleep, and broken nighttime sleep. Every drug approved before this one treated one piece of the list.
Orzeyful, made by Takeda, is a tablet taken twice a day that directly activates the same brain receptor the body’s own orexin would normally stimulate, standing in for the messenger the brain can no longer make. The FDA reviewed two randomized, double blind, placebo controlled 12-week studies enrolling 273 adults. Patients on the 2 mg dose stayed awake better during the day than those on placebo, the agency reported, with less sleepiness, fewer cataplexy episodes, and improvement across the rest of the symptom list.
The side effects deserve equal billing. The most common ones the FDA reports are insomnia, increased urinary frequency, urinary urgency, and increased saliva. Still, the FDA said few patients stopped treatment because of side effects.
Dr. Kumar’s take
This matters beyond the number of people who have narcolepsy. The orexin neurons sit in the hypothalamus, and there are very few of them relative to the rest of the brain. Narcolepsy type 1 is what happens when that small population dies, and it has been the cleanest natural experiment in sleep neuroscience for decades: take one signal away, and the wall between waking and REM sleep falls down. This approval runs it in reverse. Put a synthetic version of that signal back, and wake control returns.
Now the honest part. A drug whose most common side effect is insomnia is trading one sleep problem for another. Takeda attributes the bladder effects to the same receptor being stimulated in the brain’s urination pathways: a drug doing exactly what it was designed to do, in more places than intended.
Both trials ran 12 weeks, and narcolepsy type 1 is lifelong, so the data show the mechanism works and say almost nothing about year five. The FDA’s release also does not publish effect sizes. I read this the way I read the first double-blind trial of single-dose psilocybin for depression: a real mechanistic result, not a settled long-term treatment.
What it means for you
If you or someone in your family has narcolepsy type 1, this is worth raising with your sleep specialist, but it is not yet a prescription. The DEA has not finished assigning the controlled substance schedule, and Takeda says the drug will then go through a specialty pharmacy. Orzeyful is contraindicated with strong CYP3A inhibitors, so bring a full medication list, and its safety has not been established in anyone under 18.
If you do not have narcolepsy, nothing here changes what you should do tonight. Ordinary daytime tiredness is not narcolepsy, and the fix is still the unglamorous habits, including consistent sleep timing and eating within a narrower daily window. Takeda says it is testing other orexin drugs for narcolepsy type 2 and idiopathic hypersomnia.